 LONDON, April 01, 2021 GLOBE NEWSWIRE -- Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received PRIority MEdicines PRIME designation from the European Medicines Agency EMA for AUTO1, the companys CAR T cell therapy being investigated in the ongoing FELIX Phase 1b2 study in relapsed refractory rr adult B-Acute Lymphocytic Leukemia ALL. 